Article Topic
Pill press update: February to July 2026
Between February and July, the media covered pill press seizures in 13 states and customs forfeiture records reported seizures of 16 pill presses, six capsule-filling machines, and over 300 pill press parts, dies, and molds. Learn more about the last six months in pill press news.
[...]Tens of thousands of units of retatrutide: May & June 2026 freight fraud report
May and June 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.
[...]He just wanted to get back to work: a simple backache ended in tragedy
35-year-old Tyreek Lewis just wanted his back pain to stop, but pain relief would mean time off from work, hours of tests, and extra appointments. So he took what looked like a simple shortcut. It killed him, and altered his family’s life forever.
[...]Plea Agreement, USA v Jon Paul Dadaian
United States District Court District of New Jersey USA v Jon Paul Dadaian Plea Agreement Filed May 2022 Read the document.
[...]Mass drug compounding poses serious risks to patients
Drug compounding is intended to meet individual patient needs or temporarily bridge shortages — but the GLP-1 market has broken that model. T
[...]Statement from Partnership for Safe Medicines on new litigation alleging illegal distribution of retatrutide
Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.
[...]Statement from Partnership for Safe Medicines on the appeals court’s decision in Gilead Sciences v. Meritain Health
The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.
[...]Key takeaways from PSM’s Axios event: Examining risk and regulation in the compounded GLP-1 landscape
SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.
[...]Plea Agreement, USA v Bryce Cleveland
United States District Court Western District of Virginia USA v Bryce Cleveland Plea Agreement Filed July 2026 Read the document.
[...]PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply
PSM joined three other organizations for a sign-on letter explaining our concerns that unrestricted mass compounding increases the untraceable drug supply. An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable.
[...]